Welcome to our dedicated page for Accelerate Diagnostics news (Ticker: AXDX), a resource for investors and traders seeking the latest updates and insights on Accelerate Diagnostics stock.
Accelerate Diagnostics, Inc. (AXDX) generates news that spans product development in rapid in vitro diagnostics, regulatory milestones, financial performance, and significant corporate restructuring events. Company press releases describe a focus on solutions for antibiotic resistance and sepsis, with updates on platforms such as the Accelerate Pheno system, Accelerate PhenoTest ae BC kit, the FDA-cleared Accelerate Arc ae system and BC kit, and the development-stage Accelerate WAVE ae system.
News coverage frequently highlights clinical and regulatory progress. For example, the company has announced 510(k) clearance of the Accelerate Arc system and BC kit and the submission of the Accelerate WAVE system and Gram-negative positive blood culture test kit to the U.S. Food and Drug Administration for 510(k) clearance. Other releases describe successful pre-clinical and clinical trial milestones for the WAVE system, including performance data compared to broth microdilution reference methods and time-to-result metrics intended to support same-shift antimicrobial susceptibility reporting.
Financial news from Accelerate Diagnostics includes quarterly and full-year results, with details on net sales, gross margin, operating expenses, research and development spending, and net loss. The company has also reported on financing activities, such as debt issuances and debtor-in-possession financing commitments, as well as decisions about investor communications, including changes to its practice of hosting regular earnings conference calls.
A major theme in recent news is the companys Chapter 11 restructuring. Press releases and related SEC filings describe the voluntary Chapter 11 petitions filed in the United States Bankruptcy Court for the District of Delaware, a court-supervised sale process under Section 363 of the Bankruptcy Code, and an asset purchase agreement with an affiliate of Indaba Capital Management, L.P. Subsequent updates discuss court approval of the sale transaction, amendments to the asset purchase agreement, and confirmation of a Chapter 11 Plan of Liquidation that provides for cancellation of existing equity interests.
Visitors to this news page can review historical announcements on product clearances, trial results, financial performance, capital structure changes, and the progression of the Chapter 11 cases and asset sale. This context helps investors and observers understand how Accelerate Diagnostics diagnostic platforms and corporate structure have evolved over time.
Summary not available.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) will present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45 a.m. Eastern Time. A live webcast of the presentation will be available online. The company specializes in in vitro diagnostics, focusing on antibiotic resistance and sepsis. Its Accelerate Pheno® system reports antibiotic susceptibility results in about 7 hours, significantly faster than traditional methods. This advancement supports clinicians in optimizing patient-specific antibiotic therapy.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) published a multi-center study in Clinical Infectious Diseases, highlighting the impact of the Accelerate Pheno system on treating bloodstream infections. The study found a 17.2-hour reduction in optimal antimicrobial therapy time and a 1-day decrease in hospital stays for Gram-negative infections. Significant improvements in mortality rates and antimicrobial management were also reported. CEO Jack Phillips emphasized the system's value in healthcare, which aligns with over 70 previous studies demonstrating its efficacy.
Accelerate Diagnostics (AXDX) reported preliminary Q3 2021 results, showing a net sales decline to $3.1 million, down 13% from Q3 2020. Despite a challenging COVID environment impacting commercial execution, the company gained three contracted instruments, ending with 304 revenue-generating instruments. Gross margin decreased to 32% due to inflation in manufacturing costs. Year-to-date net sales rose to $8.4 million, a 5% increase. However, net loss year-to-date was $54.9 million, or $0.91 per share. Total cash reserves stood at $57 million, reduced outstanding debt by 30% during the quarter.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced a conference call on November 9, 2021, at 4:30 PM ET to discuss its third-quarter financial results for 2021. The call will review financial performance and operational updates, providing insights to investors and stakeholders. For audio webcasting, participants can visit ir.axdx.com. A replay will be available until February 9, 2022. The company focuses on combating antibiotic resistance and sepsis with its cutting-edge Accelerate Pheno® system.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced agreements to exchange approximately $51 million in principal amount of its 2.50% Convertible Senior Notes due 2023 for common stock. Notably, about $46 million of the Notes will yield 5,945,718 shares, while about $5 million will result in 106,732 shares plus additional shares based on a formula related to the volume-weighted average price. The transactions are set to close by October 15, 2021.
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported Q2 2021 financial results, revealing a 32% increase in net sales to $2.8 million, driven by a 35% rise in consumable revenue. However, gross margin declined to 38% from 45% due to increased manufacturing costs. The company recorded a net loss of $21.7 million or $0.36 per share. Year-to-date, net sales reached $5.3 million, an 18% increase year-over-year. Total cash reserves amounted to $68.8 million, following ongoing cost management strategies.
Accelerate Diagnostics (NASDAQ:AXDX) announces the CE marking of its new IVD configuration of the Accelerate PhenoTest® BC kit, now ready for use in Europe. This expansion follows its U.S. launch in July and provides fast antimicrobial susceptibility testing results in approximately 7 hours from positive blood cultures. The Pheno system has shown to improve clinical outcomes, including reduced hospital stays. The new configuration offers flexible workflow options for diverse laboratory settings across Europe.
Accelerate Diagnostics (NASDAQ: AXDX) announced a conference call for August 5, 2021, at 4:30 p.m. ET to discuss its second quarter financial results for 2021. Interested parties can access the audio webcast online or by phone. The replay of the call will be available until August 26, 2021. The company specializes in in vitro diagnostics, focusing on antibiotic resistance and sepsis, through its Accelerate Pheno® system. This system enables faster antibiotic susceptibility results, which could optimize patient care significantly.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) has launched a new in vitro diagnostics (IVD) configuration of its Accelerate PhenoTest® BC kit in the United States. This expansion offers fast antimicrobial susceptibility testing (AST) results in approximately 7 hours from positive blood cultures. The new configuration aims to enhance clinical outcomes by reducing the time to optimal therapy. The company plans to release this AST configuration in Europe, the Middle East, and Hong Kong later this summer, reinforcing their commitment to combating antibiotic resistance and improving sepsis treatment.